Delayed
Japan Exchange
02:00:00 2024-07-04 am EDT
|
5-day change
|
1st Jan Change
|
1,356
JPY
|
+1.80%
|
|
+1.57%
|
+6.02%
|
Fiscal Period: October |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15,629
|
51,949
|
119,696
|
82,122
|
35,225
|
26,381
|
-
|
-
|
Enterprise Value (EV)
1 |
15,629
|
50,196
|
117,288
|
78,999
|
30,541
|
26,381
|
26,381
|
26,381
|
P/E ratio
|
59.1
x
|
187
x
|
183
x
|
80.6
x
|
36.5
x
|
46.9
x
|
39
x
|
29.2
x
|
Yield
|
-
|
-
|
-
|
-
|
1.12%
|
0.3%
|
0.35%
|
0.43%
|
Capitalization / Revenue
|
9.7
x
|
28
x
|
41
x
|
19.2
x
|
7.81
x
|
5.68
x
|
5.14
x
|
4.53
x
|
EV / Revenue
|
9.7
x
|
28
x
|
41
x
|
19.2
x
|
7.81
x
|
5.68
x
|
5.14
x
|
4.53
x
|
EV / EBITDA
|
-
|
-
|
-
|
50.3
x
|
27.4
x
|
32.5
x
|
24.4
x
|
18.6
x
|
EV / FCF
|
107
x
|
177
x
|
-
|
121
x
|
120
x
|
103
x
|
43.3
x
|
31.7
x
|
FCF Yield
|
0.93%
|
0.56%
|
-
|
0.83%
|
0.83%
|
0.97%
|
2.31%
|
3.16%
|
Price to Book
|
9.72
x
|
25.6
x
|
44.4
x
|
22
x
|
5.73
x
|
4.25
x
|
3.89
x
|
3.49
x
|
Nbr of stocks (in thousands)
|
17,280
|
18,335
|
18,586
|
18,685
|
19,756
|
19,806
|
-
|
-
|
Reference price
2 |
904.4
|
2,833
|
6,440
|
4,395
|
1,783
|
1,332
|
1,332
|
1,332
|
Announcement Date
|
12/12/19
|
12/14/20
|
12/13/21
|
12/14/22
|
12/15/23
|
-
|
-
|
-
|
Fiscal Period: October |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,611
|
1,855
|
2,922
|
4,274
|
4,510
|
4,646
|
5,133
|
5,829
|
EBITDA
1 |
-
|
-
|
-
|
1,631
|
1,285
|
810.7
|
1,080
|
1,416
|
EBIT
1 |
326
|
415
|
992
|
1,571
|
1,221
|
706
|
955.3
|
1,292
|
Operating Margin
|
20.24%
|
22.37%
|
33.95%
|
36.76%
|
27.07%
|
15.2%
|
18.61%
|
22.16%
|
Earnings before Tax (EBT)
1 |
303
|
412
|
1,006
|
1,584
|
1,239
|
792
|
955
|
1,292
|
Net income
1 |
199
|
274
|
651
|
1,018
|
923
|
561.7
|
675.7
|
901.7
|
Net margin
|
12.35%
|
14.77%
|
22.28%
|
23.82%
|
20.47%
|
12.09%
|
13.16%
|
15.47%
|
EPS
2 |
15.30
|
15.19
|
35.17
|
54.54
|
48.88
|
28.40
|
34.17
|
45.57
|
Free Cash Flow
1 |
146
|
293
|
-
|
678.2
|
293
|
257
|
609
|
833
|
FCF margin
|
9.06%
|
15.8%
|
-
|
15.87%
|
6.5%
|
5.53%
|
11.87%
|
14.29%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
41.57%
|
22.8%
|
31.7%
|
56.37%
|
58.84%
|
FCF Conversion (Net income)
|
73.37%
|
106.93%
|
-
|
66.63%
|
31.74%
|
45.76%
|
90.13%
|
92.38%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
20.00
|
4.000
|
4.667
|
5.667
|
Announcement Date
|
12/12/19
|
12/14/20
|
12/13/21
|
12/14/22
|
12/15/23
|
-
|
-
|
-
|
Fiscal Period: October |
2020 S1
|
2021 S1
|
2022 Q1
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
---|
Net sales
1 |
886
|
1,343
|
820
|
1,697
|
1,175
|
1,401
|
2,577
|
1,060
|
1,111
|
2,171
|
1,236
|
1,174
|
1,054
|
2,228
|
1,130
|
1,203
|
2,508
|
1,139
|
1,172
|
1,208
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
187
|
422
|
244
|
490
|
448
|
633.1
|
1,081
|
351.3
|
308.1
|
659.3
|
384
|
205.9
|
75.61
|
281.5
|
284
|
105.5
|
593
|
149
|
183
|
198
|
Operating Margin
|
21.11%
|
31.42%
|
29.76%
|
28.87%
|
38.13%
|
45.19%
|
41.95%
|
33.15%
|
27.73%
|
30.38%
|
31.07%
|
17.54%
|
7.17%
|
12.64%
|
25.12%
|
8.77%
|
23.64%
|
13.08%
|
15.61%
|
16.39%
|
Earnings before Tax (EBT)
1 |
187
|
435
|
244
|
495
|
451
|
637.6
|
1,089
|
339.6
|
319.3
|
658.8
|
426
|
212.7
|
227.1
|
439.8
|
332
|
-146
|
-
|
149
|
183
|
198
|
Net income
1 |
118
|
268
|
155
|
308
|
281
|
428.8
|
709.8
|
216
|
194
|
410.1
|
265
|
143.9
|
156.1
|
300
|
193.5
|
59.5
|
371
|
103
|
127
|
138
|
Net margin
|
13.32%
|
19.96%
|
18.9%
|
18.15%
|
23.91%
|
30.61%
|
27.55%
|
20.39%
|
17.46%
|
18.89%
|
21.44%
|
12.26%
|
14.81%
|
13.47%
|
17.12%
|
4.95%
|
14.79%
|
9.04%
|
10.84%
|
11.42%
|
EPS
|
6.641
|
14.55
|
8.360
|
16.54
|
15.04
|
-
|
-
|
11.56
|
10.38
|
21.94
|
14.05
|
7.270
|
-
|
15.15
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/15/20
|
6/14/21
|
3/16/22
|
6/13/22
|
9/13/22
|
12/14/22
|
12/14/22
|
3/14/23
|
6/14/23
|
6/14/23
|
9/13/23
|
3/11/24
|
6/13/24
|
6/13/24
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: October |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
1,753
|
2,408
|
3,123
|
4,684
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
146
|
293
|
-
|
678
|
293
|
257
|
609
|
833
|
ROE (net income / shareholders' equity)
|
19.9%
|
15%
|
27.5%
|
31.6%
|
18.7%
|
9.13%
|
10.5%
|
12.7%
|
ROA (Net income/ Total Assets)
|
23.9%
|
19.6%
|
35.2%
|
25.6%
|
20.8%
|
10.4%
|
12.6%
|
14.7%
|
Assets
1 |
833.8
|
1,395
|
1,850
|
3,983
|
4,436
|
5,401
|
5,362
|
6,155
|
Book Value Per Share
2 |
93.00
|
111.0
|
145.0
|
200.0
|
311.0
|
313.0
|
342.0
|
381.0
|
Cash Flow per Share
2 |
20.20
|
18.80
|
38.10
|
57.80
|
53.20
|
36.00
|
45.00
|
51.00
|
Capex
1 |
49
|
37
|
55
|
99.2
|
553
|
250
|
90
|
76.7
|
Capex / Sales
|
3.04%
|
1.99%
|
1.88%
|
2.32%
|
12.26%
|
5.38%
|
1.75%
|
1.32%
|
Announcement Date
|
12/12/19
|
12/14/20
|
12/13/21
|
12/14/22
|
12/15/23
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +6.02% | 163M | | -19.73% | 8.22B | | +70.43% | 4.38B | | +12.96% | 2.81B | | -2.10% | 2.66B | | -15.14% | 1.75B | | -56.59% | 1.74B | | -16.69% | 1.47B | | +20.62% | 1.24B | | -49.43% | 1.03B |
Medical & Diagnostic Laboratories
|